Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jun;34(3):309-38.
doi: 10.1210/er.2012-1055. Epub 2013 Mar 4.

The role of estrogens in control of energy balance and glucose homeostasis

Franck Mauvais-Jarvis  1 , Deborah J Clegg, Andrea L Hevener
Affiliations
Review

The role of estrogens in control of energy balance and glucose homeostasis

Franck Mauvais-Jarvis et al. Endocr Rev. 2013 Jun.

Abstract

Estrogens play a fundamental role in the physiology of the reproductive, cardiovascular, skeletal, and central nervous systems. In this report, we review the literature in both rodents and humans on the role of estrogens and their receptors in the control of energy homeostasis and glucose metabolism in health and metabolic diseases. Estrogen actions in hypothalamic nuclei differentially control food intake, energy expenditure, and white adipose tissue distribution. Estrogen actions in skeletal muscle, liver, adipose tissue, and immune cells are involved in insulin sensitivity as well as prevention of lipid accumulation and inflammation. Estrogen actions in pancreatic islet β-cells also regulate insulin secretion, nutrient homeostasis, and survival. Estrogen deficiency promotes metabolic dysfunction predisposing to obesity, the metabolic syndrome, and type 2 diabetes. We also discuss the effect of selective estrogen receptor modulators on metabolic disorders.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Origin of circulating and tissue estrogens. A, In healthy premenopausal women, estrogen (E2) is produced by the ovaries and functions as a circulating hormone that acts on distant target tissues. Here WAT is represented. B, In postmenopausal women and in men, E2 does not function as a circulating hormone; rather, it is synthesized in extragonadal sites from circulating androgenic precursors such as T, androstenedione (4A), or dehydroepiandrosterone (DHEA). Cellular estrogenic action depends on: 1) the ER signaling and sensitivity; 2) the activity of enzymes like aromatase involved in the biosynthesis of E2 from androgenic precursors; and 3) the inactivation of E2 in E2 sulfate (E2-S) by the estrogen sulfotransferase (EST).
Figure 2.
Figure 2.
Summary of hypothalamic ERα actions regulating energy balance. In the hypothalamus, estrogen action through ERα in ARC POMC neurons suppresses food intake. On the other end, estrogen actions through ERα in VMN SF1 neurons stimulate physical activity and energy expenditure and regulate body fat distribution.
Figure 3.
Figure 3.
Consequences of ERα deletion in skeletal muscle on metabolic dysfunction. Skeletal muscle-specific ERα deletion impairs muscle metabolism, leading to increased accumulation of bioactive lipids and muscle inflammation, which impairs muscle insulin action. Because skeletal muscle is a primary tissue responsible for fatty acid oxidation, impaired substrate oxidation promotes increased accumulation of fat in adipose tissue, which alters the secretory signature of the tissue inducing secondary phenotypes in muscle and liver. Thus, muscle ERα deletion precipitates impaired glucose tolerance and mild hepatic insulin resistance. The arrows represent the effect of skeletal muscle, adipose, and liver described above on each other.
Figure 4.
Figure 4.
Summary of estrogen actions in glucose homeostasis and energy metabolism in physiology and menopause. Estrogen actions in the brain, adipose, pancreatic islets, skeletal muscle, liver, and macrophages synergize to promote glucose and lipid homeostasis. Estrogen deficiency or resistance in these tissues all contribute to metabolic dysfunction predisposing to the metabolic syndrome, type 2 diabetes, and obesity.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med. 1999;130:545–553. - PubMed
    1. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. 1975;293:1167–1170. - PubMed
    1. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med. 1975;293:1164–1167. - PubMed
    1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333. - PubMed
    1. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010;95(7 suppl 1):s1–s66. - PMC - PubMed

Publication types

MeSH terms